Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Bought by Franklin Resources Inc.

Franklin Resources Inc. lifted its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 358.8% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 92,921 shares of the biotechnology company’s stock after acquiring an additional 72,668 shares during the period. Franklin Resources Inc. owned approximately 0.06% of Aurinia Pharmaceuticals worth $834,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. State Street Corp grew its position in Aurinia Pharmaceuticals by 2.3% during the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock worth $21,587,000 after purchasing an additional 64,949 shares during the last quarter. Barclays PLC grew its holdings in shares of Aurinia Pharmaceuticals by 187.6% during the third quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock valued at $1,607,000 after buying an additional 143,072 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 6,174 shares during the last quarter. Atria Wealth Solutions Inc. acquired a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $135,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Aurinia Pharmaceuticals in the 4th quarter worth $9,662,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Trading Up 0.3 %

NASDAQ AUPH opened at $7.75 on Wednesday. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The company has a market capitalization of $1.06 billion, a PE ratio of -51.66 and a beta of 1.20. The company has a fifty day moving average of $8.00 and a 200 day moving average of $8.10.

Insider Buying and Selling at Aurinia Pharmaceuticals

In related news, insider Greg Keenan sold 12,239 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $97,912.00. Following the completion of the transaction, the insider now directly owns 161,789 shares in the company, valued at $1,294,312. The trade was a 7.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Peter Greenleaf sold 195,593 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the sale, the chief executive officer now owns 1,953,892 shares in the company, valued at approximately $15,631,136. This represents a 9.10 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 343,898 shares of company stock worth $2,753,094. Insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 27th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.